Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
Adalimumab is a humanized recombinant monoclonal antibody fragment targeted against tumor
necrosis factor. This study will assess the safety and efficacy of intravitreal adalimumab
administered in patients with choroidal neovascularization secondary to age-related macular
degeneration non-responders to the conventional treatment with intravitreal ranibizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Hospital Universitari Vall d'Hebron Research Institute